Welcome

- Audio for this event is available via ReadyTalk[®] Internet streaming.
- No telephone line is required.
- Computer speakers or headphones are necessary to listen to streaming audio.
- Limited dial-in lines are available.
 Please send a chat message if needed.
- This event is being recorded.




Troubleshooting Audio

Audio from computer speakers breaking up? Audio suddenly stop?

- Click Refresh icon
 - or -
 - Click F5






Location of Buttons



Troubleshooting Echo


- Hear a bad echo on the call?
- Echo is caused by multiple browsers/tabs open to a single event – multiple audio feeds.
- Close all but one browser/tab and the echo will clear.



LACINIPIE OF TWO DIOWSELS/ TODS OPEN IN SOME LYCHA

Submitting Questions

Type questions in the "Chat with Presenter" section, located in the bottom-left corner of your screen.





PCHQR Program An Overview of Best Practices to Mitigate Chemotherapy-Related Adverse Events

Tom Ross, MS

Program Lead

PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program Hospital Inpatient Values, Incentives, and Quality Reporting (VIQR) Outreach and Education Support Contractor (SC)

May 25, 2017

Acronyms and Abbreviations

ACS	American College of Surgeons	ICD	International Classification of Diseases
ADCC	Alliance of Dedicated Cancer Centers	ICU	Intensive Care Unit
ADT	Androgen Deprivation Therapy	IDSA	Infectious Diseases Society of America
AMA	American Medical Association	IPPS	Inpatient Prospective Payment System
ASCO	American Society of Clinical Oncology	IQR	Inpatient Quality Reporting
ASH	American Society of Hematology	LabID	Laboratory-Identified
CAUTI	Catheter-Associated Urinary Tract Infection	LTCH	Long-Term Care Hospital
CDC	Centers for Disease Control and Prevention	MIF	Measure Information Form
CCN	CMS Certification Number	MRSA	Methicillin-Resistant Staphylococcus aureus
CDI	Clostridium difficile Infection	MUC	Measures Under Consideration
CE	Continuing Education	N/A	Not Available
CLABSI	Central Line-Associated Bloodstream Infection	NHSN	National Healthcare Safety Network
CMS	Centers for Medicare & Medicaid Services	NCCN	National Comprehensive Cancer Network
CPT	Current Procedural Terminology	NQF	National Quality Forum
CST	Cancer-Specific Treatment	NQS	National Quality Strategy
CY	Calendar Year	OCM	Oncology Care Measure
DACA	Data Accuracy and Completeness Acknowledgement	ONS	Oncology Nursing Society
EBRT	External Beam Radiotherapy	OQR	Outpatient Quality Reporting
ECE	Extraordinary Circumstances Extension / Exception	PCH	PPS-Exempt Cancer Hospital
ED	Emergency Department	PCHQR	PPS-Exempt Cancer Hospital Quality Reporting
EOL	End of Life	PEP	Putting Evidence Into Practice
EPIC	Expanded Prostate Inventory Composite	PQRS	Physician Quality Reporting System
FFS	Fee-for-Service	PR	Public Reporting
FY	Fiscal Year	Q	Quarter
Fxns	Fractions	RSAR	Risk-Standardized Admission Rate
Gy	Gray	RSEDR	Risk-Standardized ED Visit Rate
HAI	Healthcare-Associated Infection	SBRT	Stereotactic Body Radiation Therapy
HCAHPS		SRS	Stereotactic Radiosurgery
HCD	Providers and Systems	SSI	Surgical Site Infection
HCP	Healthcare Personnel	TEP	Technical Expert Panel
HHS	US Department of Health and Human Services	TBD	To Be Determined
HQR	Hospital Quality Reporting	WBDCT	Web-Based Data Collection Tool

Purpose

This presentation will provide a review of the most commonly cited reasons associated with hospital visits among cancer outpatients and an overview of the best practices to manage these events. The goal is to provide PCHQR Program participants with a framework to mitigate potentially preventable admissions and ED visits for patients receiving outpatient chemotherapy.

Objectives

Upon completion of this program, participants will be able to perform the following:

- Summarize the rationale for the inclusion of the Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy measure in the PCHQR Program
- List the most commonly cited reasons for hospital visits among cancer outpatients
- Discuss the best practices that may be implemented to mitigate the occurrence of such adverse events

Measure Overview

The Admissions and ED Visits for Patients Receiving Outpatient Chemotherapy measure:

- Became effective for FY 2019 program and subsequent years
 Begin with data from July 1, 2016, through June 30, 2017, and then use data from July 1 through June 30 for subsequent years
- Aims to assess care provided to cancer patients and encourage quality improvement efforts

Reduce the number of unplanned inpatient admissions and ED visits among cancer patients receiving chemotherapy in a PCH outpatient setting

- Addresses two National Quality Strategy priorities
 - Promote effective communication and coordination of care
 - Promote the most effective prevention and treatment practices for the leading causes of mortality
- Focuses on results that matter to patients

Basics of the New Measure

The Admissions and ED Visits for Patients Receiving Outpatient Chemotherapy measure:

- Is a risk-standardized outcome measure for patients 18 years or older who are receiving PCH-based outpatient chemotherapy treatment for all cancer types except for leukemia
- Will utilize one year of Medicare FFS Parts A and B administrative claims data
- Requires that the qualifying diagnosis on the admission or ED visit claim be the primary diagnosis or a secondary diagnosis accompanied by a primary diagnosis of cancer

Basics of the New Measure (Cont.)

The Admissions and ED Visits for Patients Receiving Outpatient Chemotherapy measure:

- Has a window for identifying events limited to 30 days after PCH outpatient chemotherapy treatment encounters
- Identifies outcomes separately for the inpatient and ED measures

Note: A patient can only qualify once for one of the two outcomes in each measurement period. If a patient experiences both outcomes, the measure counts toward the inpatient admission.

Measure Exclusions

The Admissions and ED Visits for Patients Receiving Outpatient Chemotherapy measure does not include procedure codes for oral chemotherapy.

The measure excludes patients who:


- Have a diagnosis of leukemia at any time during the measurement period
- Were not enrolled in Medicare FFS Parts A and B in the year before the first outpatient chemotherapy encounter
- Do not have at least one outpatient chemotherapy treatment encounter followed by continuous enrollment in Medicare FFS Parts A and B in 30 days after the encounter

Measure Analysis

The Admissions and ED Visits for Patients Receiving Outpatient Chemotherapy measure:

Uses hierarchical logistic modeling

Is calculated as



National Observed Rate (PCH)

- Is reported as two PCH-level rates
 - o RSAR
 - o RSEDR

Reporting for the Measure

Reporting for the Admissions and ED Visits for Patients Receiving Outpatient Chemotherapy includes:

- Public reporting of RSAR and RSEDR for all participating PCHs with 25 or more eligible patients per measurement period
- Conducting a confidential national reporting (dry run) of measure results prior to public reporting to:
 - Educate PCHs and other stakeholders
 - Allow PCHs to review their results prior to public reporting
 - Answer questions about the measure
 - Test the production and reporting process
 - Identify technical changes that may be needed

Measure Specifications

The full measure specifications are found on the <u>CMS.gov Measure Methodology page</u>.

Locate the document, "Admissions and Emergency Department Visits for Patients Receiving Outpatient Chemotherapy, Measure Technical Report," dated March 2016.

Planned Events

Events are coordinated by the measure development team and all dates are tentative.

- Dry run of confidential national reporting conducted late summer to early fall 2017
- Distribution of facility-specific reports
- National Provider Call
- Evaluation of and response to inquiries
- Public reporting of data not yet been determined

Anticipated Impact

The Admissions and ED Visits for Patients Receiving Outpatient Chemotherapy measure is anticipated to impact:

- Quality of life for patients and families
 - Physical and emotional well-being
 - Disruption of schedules
 - Decreased desire to work and engage in social activities
 - Increased burden on family
- Population and fiscal issues
 - 1.6 million new cancer cases in 2015
 - 22% of cancer patients receive chemotherapy
 - From 2008 to 2012, the proportion of Medicare patients receiving hospital-based outpatient chemotherapy increased from 18 to 29%
 - Medicare payments for cancer treatment totaled \$34.4 billion in 2010, or almost 10% of Medicare FFS
 - National average costs
 - \$22,000 for chemotherapy-related admission
 - \$800 for chemotherapy-related ED visit

Potentially Preventable Chemotherapy-Associated Adverse Events Causing Admissions and ED Visits

Adverse Events			
Anemia	Nausea		
Dehydration	Neutropenia		
Diarrhea	Pain		
Emesis	Pneumonia		
Fever	Sepsis		

Opportunities to Minimize the Need for Acute Hospital Care for Chemotherapy-Associated Adverse Events

Evidence-based interventions are currently available from several organizations:

- American Society of Clinical Oncology
- National Comprehensive Cancer Network
- Oncology Nursing Society
- Infectious Diseases Society of America
- Other professional societies

American Society of Clinical Oncology (ASCO)

ASCO Guidelines, Tools, & Resources

- Guidelines by Clinical Area
- Assays & Predictive Marks
- Disease Specific
- Patient & Survivor Care
- Resource-Stratified
- Supportive Care and Treatment Related Issues

ASCO Supportive Care and Treatment Related Issues

- Antiemetics Focused Update
- Recommendations for the Use of WBC Growth Factors Update
- Central Venous Catheter Care for the Patient With Cancer
- Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy
- Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem Cell Transplantation Guideline Endorsement
- ASCO-ASH Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer

National Comprehensive Cancer Network (NCCN)

- The <u>NCCN</u> is a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education.
- Many educational tools available including guidelines for:
 - Treatment of Cancer by Site
 - Detection, Prevention, & Risk Reduction
 - Supportive Care
 - Age Related Recommendations

Patients

5/25/2017 22

NCCN Guidelines for Supportive Care

- Adult Cancer Pain
- Antiemesis
- Cancer- and Chemotherapy-Induced Anemia
- Myeloid Growth Factors
- Prevention and Treatment of Cancer-Related Infections

5/25/2017 23

Oncology Nursing Society (ONS)

- The <u>ONS</u> is a professional association of more than 39,000 members committed to promoting excellence in oncology nursing and the transformation of cancer care.
- Multiple resources available
 - Continuing Nursing Education
 - Practice Resources
 - Publications
 - Cancer Therapies
 - Putting Evidence Into Practice (PEP)

ONS PEP Modules

- Chemotherapy-Induced Nausea and Vomiting
- Diarrhea
- Fatigue
- Mucositis
- Pain
- Prevention of Infection

Infectious Diseases Society of America (IDSA)

- The <u>IDSA</u> represents physicians, scientists and other health care professionals who specialize in infectious diseases. IDSA's purpose is to improve the health of individuals, communities, and society by promoting excellence in patient care, education, research, public health, and prevention relating to infectious diseases.
- IDSA Practice Guidelines
 - Neutropenic Patients with Cancer
 - Management of Catheter-related Infections
 - Opportunistic Infections in Stem Cell Transplant Recipients
 - Vaccination of the Immunocompromised Host
 - Fever and Neutropenia
 - Organism-specific Guidelines

Other Potential Resources

- Centers for Disease Control and Prevention (CDC)
 - Preventing Infections in Cancer Patients
 - Scholarly articles related to infections in cancer patients
- Professional Societies
 - American Pain Society
 - American Society of Hematology
- Professional Organizations
 - Alliance of Dedicated Cancer Centers
 - Consortium of Comprehensive Cancer Centers for Quality Improvement

Primary literature and literature reviews

Call for Best Practices

- Desire to hold three or four events during remainder of 2017, focusing on best practices to mitigate adverse events associated with outpatient chemotherapy
- Please nominate best practices to the VIQR SC
- First event scheduled for July 2017

PCHQR Program
An Overview of Best Practices to Mitigate
Chemotherapy-Related Adverse Events

Miscellaneous Notes

Important Upcoming Events

Currently Scheduled 2017 Webinars

- June 22: PCHQR Program: Web-Based Data Collection Tool II
- July 27: PCHQR Program: Best Practice I
- August 24: PCHQR Program: FY 2018 IPPS/LTCH Final Rule
- September 28: PCHQR Program: Best Practice II
- October 26: TBD
- November 16: TBD
- December 21: TBD

Important Upcoming Dates

Upcoming HQR Data Submissions

- July 5, 2017: Q1 2017 HCAHPS data
- August 15, 2017:
 - Q4 2016 CST chemo (colon and breast) data
 - o Q2 2016 CST hormone data
 - Q1 through Q4, 2016 OCM and EBRT data
 - o Q1 2017 HAI data
- August 31, 2017: FY 2018 DACA
- October 4, 2017: Q2 2017 HCAHPS data

Important Upcoming Dates (Cont.)

Hospital Compare Key Dates

- July 2017
 - Contains:
 - 2Q 2015 through 1Q 2016 chemo data
 - 4Q 2014 through 3Q 2015 hormone data
 - 1Q through 4Q 2015 EBRT data
 - 4Q 2015 through 3Q 2016 HCAHPS data
 - Anticipated refresh on July 26

October 2017

- o Contains:
 - 3Q 2015 through 2Q 2016 chemo data

 - 1Q 2015 through 4Q 2015 hormone data
 1Q 2016 through 4Q 2016 HCAHPS data
- Preview period scheduled for July 14 through August 13
- Anticipated refresh on October 18

Continuing Education Approval

This program has been approved for 1.0 continuing education (CE) unit for the following professional boards:

- Florida Board of Clinical Social Work, Marriage & Family Therapy and Mental Health Counseling
- Florida Board of Nursing Home Administrators
- Florida Dietetics and Nutrition Practice Council
- Florida Board of Pharmacy
- California Board of Registered Nursing (Provider #16578)
 - It is your responsibility to submit this form to your accrediting body for credit.

CE Credit Process


- Complete the ReadyTalk® survey that will pop up after the webinar, or wait for the survey that will be sent to all registrants within the next 48 hours.
- After completion of the survey, click "Done" at the bottom of the screen.
- Another page will open that asks you to register in the HSAG Learning Management Center.
 - This is a separate registration from ReadyTalk[®].
 - Please use your personal email so you can receive your certificate.

Healthcare facilities have firewalls up that block our certificates.


CE Certificate Problems?

- If you do not immediately receive a response to the email that you signed up with in the Learning Management Center, you have a firewall up that is blocking the link that was sent.
- Please go back to the New User link and register your personal email account.
 - Personal emails do not have firewalls.


CE Credit Process: Survey




CE Credit Process: Certificate



CE Credit Process: New User



CE Credit Process: Existing User



Questions

Disclaimer

This presentation was current at the time of publication and/or upload onto the *Quality Reporting Center* and *QualityNet* websites. Medicare policy changes frequently. Any links to Medicare online source documents are for reference use only. In the case that Medicare policy, requirements, or guidance related to this presentation change following the date of posting, this presentation will not necessarily reflect those changes; given that it will remain as an archived copy, it will not be updated.

This presentation was prepared as a service to the public and is not intended to grant rights or impose obligations. Any references or links to statutes, regulations, and/or other policy materials included in the presentation are provided as summary information. No material contained therein is intended to take the place of either written laws or regulations. In the event of any conflict between the information provided by the presentation and any information included in any Medicare rules and/or regulations, the rules and regulations shall govern. The specific statutes, regulations, and other interpretive materials should be reviewed independently for a full and accurate statement of their contents.

5/25/2017 41